Acyclovir use and survival among human immunodeficiency virus-infected patients with CD4 cell counts of <500/mm3

Clinical Infectious Diseases

Volumn 26, Issue 1, 1998, Pages 85-90

  Torres, Ramón A ^a   Neaton, James D ^b   Wentworth, Deborah N ^b   Barr, Michael R ^b   Abrams, Donald ^b   Sherer, Renslow ^b   Ward, Thomas ^b   Sampson, James ^b  

^a ST VINCENT S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; FOLLOW UP; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; SURVIVAL RATE; VARICELLA ZOSTER VIRUS;

EID: 0031941401     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/516272     Document Type: Article

References (12)

1. Cooper DA, Pehrson PO, Pedersen C, et al. The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind, randomized trial. AIDS 1993;7:197-207.
2. Youle MS, Gazzard BG, Johnson MA, et al. Effects of high-dose oral acyclovir on herpesvirus disease and survival in patients with advanced HIV disease: a double-blind, placebo-controlled study. AIDS 1994; 8: 641-9.
3. Collier AC, Schoenfeld DA, Bourland D, Hirsch M, Davis LG, Corey L. Prospective comparative study of acyclovir (ACV) and zidovudine (ZDV) versus ZDV alone in patients with AIDS. In: Abstracts of the 2nd National Conference on Human Retroviruses and Related Infections. Washington, DC: American Society for Microbiology, 1995:383.
4. Stein DS, Graham NMH, Park LP, et al. The effect of the interaction of acyclovir with zidovudine on progression to AIDS and survival: analysis of data in the multicenter AIDS cohort study. Ann Intern Med 1994; 121:100-8.
5. Gallant JE, Moore RD, Keruly J, Richman DD, Chaisson RE, the Zidovudine Epidemiology Study Group. Lack of association between acyclovir use and survival in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis 1995;172:346-52.
6. Erbelding EJ, Chaisson RE, Gallant JE, Moore RD. Acyclovir in combination with zidovudine does not prolong survival in advanced HIV disease. Antiviral Therapy 1997;2:71-7.
7. Golden MP, Kim S, Hammer SM, et al. Activation of human immunodeficiency virus by herpes simplex virus. J Infect Dis 1992;166:494-9.
8. Mole L, Ripich S, Margolis D, Holodniy M. Plasma HIV RNA levels are increased during active herpes simplex virus infection. In: Abstracts of the 2nd National Conference on Human Retroviruses and Related Infections. Washington, DC: American Society for Microbiology, 1995: 239.
9. Carlyn M, Cohen C. CPCRA/CBCTN observational database project: a major community-based research project on HIV infection [abstract F. B. 439]. In: Program and abstracts of the 6th International Conference on AIDS (San Francisco). Washington, DC: American Society for Microbiology, 1990.
10. Fisher LD, van Belle G. Biostatistics: a methodology for the health sciences. New York: John Wiley & Sons, 1993.
11. Cox DR. Regression models and life tables. J Stat Soc 1972;34:187-220.
12. Price R, Daniels K, Rhame F, et al. Progression of HIV disease: definitions, criteria, and data processing systems of CPCRA [abstract PoC 4510]. In: Program and abstracts of the 8th International Conference on AIDS (Amsterdam). Amsterdam: CONGREX Holland BV, 1992.